Known targets — ChEMBL curated mechanism
ACHECHKACHRM1CHRM2CHRM3CHRM4CHRM5CHRNA1CHRNB1CHRNDCHRNECHRNGHRH2OPRM1
The experimentally established mechanism targets of Bromide. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRM2 known ✓ | P08172 | 2/20 | 0.55 |
| ▸ | CHRM1 known ✓ | P11229 | 2/20 | 0.55 |
| ▸ | ACHE known ✓ | P22303 | 2/20 | 0.55 |
| ▸ | CHRM4 known ✓ | P08173 | 1/20 | 0.55 |
| ▸ | CHRM5 known ✓ | P08912 | 1/20 | 0.55 |
| ▸ | CHRM3 known ✓ | P20309 | 1/20 | 0.55 |
| ▸ | OPRM1 known ✓ | P35372 | 1/20 | 0.52 |
| ▸ | KMT2A | Q03164 | 5/20 | 0.63 |
| ▸ | HTT | P42858 | 4/20 | 0.63 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.63 |
| ▸ | MEN1 | O00255 | 4/20 | 0.63 |
| ▸ | HSP90AA1 | P07900 | 4/20 | 0.63 |
| ▸ | MAPT | P10636 | 3/20 | 0.63 |
| ▸ | MAPK1 | P28482 | 3/20 | 0.63 |
| ▸ | APAF1 | O14727 | 2/20 | 0.63 |
| ▸ | BLM | P54132 | 1/20 | 0.63 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.63 |
| ▸ | TP53 | P04637 | 1/20 | 0.60 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.60 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.60 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Bromide SCHEMBL692643 | 1.00 | KMT2A (0.63) | KMT2AHTTSMN1; SMN2MEN1HSP90AA1 | |
| Bromide SCHEMBL3703072 | 1.00 | KMT2A (0.63) | KMT2AHTTSMN1; SMN2MEN1HSP90AA1 | |
| Bromide SCHEMBL9819629 | 1.00 | KMT2A (0.63) | KMT2AHTTSMN1; SMN2MEN1HSP90AA1 | |
| SCHEMBL6929941 | 0.98 | KMT2A (0.62) | KMT2AHTTSMN1; SMN2MEN1HSP90AA1 | |
| SCHEMBL3392127 | 0.98 | KMT2A (0.62) | KMT2AHTTSMN1; SMN2MEN1HSP90AA1 | |
| SCHEMBL19582712 | 0.98 | KMT2A (0.62) | KMT2AHTTSMN1; SMN2MEN1HSP90AA1 | |
| SCHEMBL2786767 | 0.98 | KMT2A (0.62) | KMT2AHTTSMN1; SMN2MEN1HSP90AA1 | |
| SCHEMBL588400 | 0.98 | KMT2A (0.62) | KMT2AHTTSMN1; SMN2MEN1HSP90AA1 | |
| Hydrochloric Acid SCHEMBL8027797 | 0.96 | KMT2A (0.60) | KMT2AHTTSMN1; SMN2MEN1HSP90AA1 | |
| Hydrochloric Acid SCHEMBL9614521 | 0.96 | KMT2A (0.60) | KMT2AHTTSMN1; SMN2MEN1HSP90AA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1283727-A4 | COMPOSITIONS AND METHODS FOR INDUCING ACTIVATION OF DENDRITIC CELLS | SUPRATEK PHARMA INC (CA) | 2007-10-10 | — | — | EP | disclosed |
| US-7256180-B2 | Compositions and methods for inducing activation of dendritic cells | SUPRATEK PHARMA INC. (CA) | 2007-08-14 | — | — | US | disclosed |
| EP-0789564-B1 | POLYNUCLEOTIDE COMPOSITIONS | SUPRATEK PHARMA INC (CA) | 2006-03-22 | — | — | EP | disclosed |
| US-20030198678-A1 | Polynucleotide compositions | KABANOV ALEXANDER V (US) | 2003-10-23 | — | — | US | disclosed |
| EP-1140015-A4 | POLYNUCLEOTIDE COMPOSITIONS FOR INTRAMUSCULAR AND INTRADERMAL ADMINISTRATION | SUPRATEK PHARMA INC (CA) | 2003-08-06 | — | — | EP | disclosed |
| US-20030118550-A1 | Compositions and methods for inducing activation of dendritic cells | SUPRATEK PHARMA INC. (CA) | 2003-06-26 | — | — | US | disclosed |
| EP-1283727-A2 | COMPOSITIONS AND METHODS FOR INDUCING ACTIVATION OF DENDRITIC CELLS | SUPRATEK PHARMA, INC. (CA) | 2003-02-19 | — | — | EP | disclosed |
| US-6440743-B1 | SUPPLYING IMMOBILIZATED POLYNUCLEOTIDES | SUPRATEK PHARMA INC. (CA) | 2002-08-27 | — | — | US | disclosed |
| US-6359054-B1 | FOR GENE THERAPY | SUPRATEK PHARMA INC. | 2002-03-19 | — | — | US | disclosed |
| US-6353055-B1 | Polynucleotide compositions | SUPRATEK PHARMA INC. (CA) | 2002-03-05 | — | — | US | disclosed |
| WO-2001083698-A2 | COMPOSITIONS AND METHODS FOR INDUCING ACTIVATION OF DENDRITIC CELLS | SUPRATEK PHARMA, INC. (CA) | 2001-11-08 | — | — | WO | disclosed |
| EP-1140015-A1 | POLYNUCLEOTIDE COMPOSITIONS FOR INTRAMUSCULAR AND INTRADERMAL ADMINISTRATION | SUPRATEK PHARMA, INC. (CA) | 2001-10-10 | — | — | EP | disclosed |
| US-6221959-B1 | POLYNUCLEOTIDE, POLYMER COMPLEX | SUPRATEK PHARMA, INC. (CA) | 2001-04-24 | — | — | US | disclosed |
| EP-0789564-A4 | POLYNUCLEOTIDE COMPOSITIONS | SUPRATEK PHARMA INC (CA) | 2000-11-08 | — | — | EP | disclosed |
| WO-2000047186-A1 | POLYNUCLEOTIDE COMPOSITIONS FOR INTRAMUSCULAR AND INTRADERMAL ADMINISTRATION | SUPRATEK PHARMA INC. (CA) | 2000-08-17 | — | — | WO | disclosed |
| EP-0789564-A1 | POLYNUCLEOTIDE COMPOSITIONS | SUPRATEK PHARMA, INC. (CA) | 1997-08-20 | — | — | EP | disclosed |
| US-5656611-A | MODIFIED POLYNUCLEOTIDE AND COPOLYMER HAVING POLYETHER SEGMENTS AND POLYCATION SEGMENTS; STABILIZING POLYNUCLEIC ACIDS AND INCREASING ABILITY TO CROSS CELL MEMBRANES | SUPRATEK PHARMA INC. (CA) | 1997-08-12 | — | — | US | disclosed |
| WO-1996015778-A1 | POLYNUCLEOTIDE COMPOSITIONS | SUPRATEK PHARMA, INC. (CA) | 1996-05-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030118550-A1 | Compositions and methods for inducing activation of dendritic cells | TLR7, TLR3, TLR9 | CHRM2 1354/4885CHRM1 817/4885ACHE 4230/4885 |
| US-20030198678-A1 | Polynucleotide compositions | POLN, POLI, PCNA | CHRM2 4431/4885CHRM1 4523/4885ACHE 4659/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.